Do You Need a 510(k) or De Novo? Choosing the Right FDA Pathway for Medical Devices

Bringing a medical device to the US market requires selecting the correct FDA regulatory pathway—and this decision can determine your approval timeline, cost, and overall success.

Two of the most common pathways are: -> 510(k) Premarket Notification -> De Novo Classification Request

Choosing between them is not always straightforward. The decision depends on your device’s risk classification, novelty, and predicate availability.

Making the wrong choice can lead to: -> Delays in approval -> Increased costs -> Rejection or re-submission

In this guide, we will help you clearly understand: -> What 510(k) and De Novo pathways are -> Key differences -> When to choose each -> Strategic considerations for faster approval

What is a 510(k) Submission?

A 510(k) is the most common FDA pathway used to demonstrate that your device is substantially equivalent to an already legally marketed device (predicate device).

👉 This pathway is ideal when your device: -> Has similar intended use as an existing device -> Uses comparable technology -> Does not raise new safety concerns

If your device fits this category, you can follow the 510(k) submission process to gain market clearance.

What is a De Novo Request?

The De Novo pathway is used for novel medical devices that: -> Do not have a predicate device -> Are considered low to moderate risk

Instead of rejecting your application due to lack of predicate, the FDA allows classification through De Novo.

👉 This pathway creates a new device classification, which future devices can reference.

Key Differences Between 510(k) and De Novo

👉 In simple terms: -> 510(k) = Faster route using existing device comparison -> De Novo = New classification for innovative devices

How FDA Device Classification Impacts Your Pathway

Before choosing a pathway, you must determine your device classification.

The FDA categorizes devices into: -> Class I (low risk) -> Class II (moderate risk) -> Class III (high risk)

When Should You Choose a 510(k)?

You should opt for 510(k) when: -> A predicate device exists -> Your device has similar intended use -> Technology differences are minimal -> Safety and performance are well established

👉 A strong predicate device selection strategy is critical here—poor selection can lead to rejection or delays.

When Should You Choose De Novo?

De Novo is the right choice when: -> No predicate device is available -> Your device is innovative but low/moderate risk -> FDA classifies your device as “Not Substantially Equivalent (NSE)”

👉 In many cases, companies first submit a 510(k) and receive NSE—then proceed with De Novo.

Decision-Making Framework (Simple Approach)

Use this simplified logic: Is there a similar device already on the market? → YES → Go for 510(k) No predicate device? → Consider De Novo Is the device high risk? → PMA pathway (separate process)

👉 This decision must be supported by proper regulatory assessment and documentation.

Common Mistakes When Choosing FDA Pathways

Choosing the wrong pathway is a common issue.

❌ Selecting Incorrect Predicate Device

Leads to rejection or additional queries.

❌ Ignoring Device Classification

Misclassification affects entire submission strategy.

❌ Underestimating De Novo Requirements

Requires more detailed data and justification.

❌ Poor Documentation

Impacts both pathways and delays approval.

👉 These mistakes often result in increased costs and longer timelines.

How This Decision Impacts Cost and Timeline

Your pathway directly affects:

510(k):

De Novo:

👉 Understanding this helps in planning your FDA Medical Device User Fees (MDUFA) and overall budget.

How OMC Medical Can Help

Selecting the right FDA pathway requires expertise and strategic planning.

OMC Medical provides: -> Regulatory pathway assessment -> Predicate device identification -> 510(k) and De Novo submission support -> Documentation and technical file preparation -> End-to-end FDA compliance strategy

👉 Our experts help you choose the fastest and most cost-effective pathway, reducing risks and accelerating approval.

Conclusion

Choosing between 510(k) and De Novo is a critical regulatory decision that impacts your product’s success in the US market. If your device is similar to an existing one → 510(k) If your device is novel but low risk → De Novo

A clear understanding of classification, predicate devices, and regulatory expectations ensures a smoother approval process.

FAQs

Q1. Can I switch from 510(k) to De Novo?
Yes, especially if your 510(k) is found Not Substantially Equivalent (NSE).

Q2. Which pathway is faster?
510(k) is generally faster than De Novo.

Q3. Is De Novo more expensive?
Yes, due to higher data and documentation requirements.

Q4. Do all devices need 510(k)?
No, some are exempt, and others follow De Novo or PMA pathways.